0
0
0
0
1
2
3
$0
Is Sempra solid or fragile? The Finex Financial Health Scanner reads SRE's real financial statements and scores its debt, liquidity, margins, cash flow and growth, with the Altman Z-score, the Piotroski F-score and the red flags explained in plain words.
| Revenue (FY2025) | $13.7B |
|---|---|
| Net income | $1.8B |
| Operating margin | 17.7% |
| Net margin | 13.4% |
| Cash and investments | $31.0M |
| Total debt | $35.0B |
| Free cash flow | -$11.4B |
| Revenue growth (1 year) | 3.9% |
Data: Nasdaq and Yahoo Finance. Educational, not financial advice.